Amazon Biotech in talks to initiate HIV drug sales in Africa

22 December 2006

The USA's Amazon Biotech says it is in negotiations with an undisclosed European company to obtain approvals to sell its AIDS drug in Nigeria and Kenya.

Amazon is a natural plant pharmaceutical company, primarily developing immune modulator drugs. AMZ0026 is its first such drug, which is intended for the treatment of HIV/AIDS. The company plans on initiating Phase I/II clinical studies of the agent "in the near future," with an eventual goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials, or following the US Food and Drug Administration Fast Track program to market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight